Financings in Brief: Gliatech
This article was originally published in The Gray Sheet
Gliatech: Nets $19.8 mil. from initial public offering of 2.3 mil. shares at $9.50 a share. The issue will be traded on the NASDAQ exchange under the symbol "GLIA," the firm states. Cleveland-based Gliatech announced plans for the IPO during the summer ("The Gray Sheet" Sept. 11, p. 13). Net proceeds will go toward manufacturing and marketing in Europe of the Cleveland-based firm's Adcon line of products to control surgical adhesion, clinical trials of the products in the U.S. and Europe, working capital and general corporate purposes. The offering was managed by Montgomery Securities, Vector Securities International, and McDonald & Company Securities...
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.